Research Areas

Researchers are turning bacterial transport systems from obstacles into opportunities for targeted therapy.

Pulmonary fibrosis patients have long suffered through side effects from their drugs. That could change with the potential for new inhaled versions in clinical trials.

Acquisition brings Avidity’s RNA delivery platform and late-stage neuromuscular programs under Novartis, expanding its capabilities in developing precision genetic medicines.

Qureight’s Vascul8 model uses AI to analyse CT scans and identify patients at risk of residual pulmonary hypertension after surgery.

Scientists are using insights from viral hijacking to chemically reprogram E3 ligases, opening new opportunities in drug discovery.

Researchers highlight how intra-tumoral microbiota shape tumor growth, drug resistance, and treatment response.

Lonza strengthens its pharmaceutical quality control portfolio through the acquisition of Redberry, enabling faster and more reliable microbial testing.

Ongoing collaboration aims to bring new treatments for neurodegenerative conditions closer to patients.

Ryvu’s ONCO Prime platform uncovers novel molecular vulnerabilities and actionable targets in colorectal and other cancers.

Multibillion dollar oncology deals, first-in-class wins, AI scientists, and more led the news this week.